Skip to main content

Peer Review reports

From: Median effective dose of esketamine for intranasal premedication in children with congenital heart disease

Original Submission
1 Jun 2022 Submitted Original manuscript
8 Jun 2022 Author responded Author comments - Hongbin Gu
Resubmission - Version 2
8 Jun 2022 Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
4 Aug 2022 Reviewed Reviewer Report
5 Sep 2022 Reviewed Reviewer Report
5 Oct 2022 Reviewed Reviewer Report
18 Oct 2022 Author responded Author comments - Hongbin Gu
Resubmission - Version 4
18 Oct 2022 Submitted Manuscript version 4
26 Oct 2022 Author responded Author comments - Hongbin Gu
Resubmission - Version 5
26 Oct 2022 Submitted Manuscript version 5
27 Oct 2022 Author responded Author comments - Hongbin Gu
Resubmission - Version 6
27 Oct 2022 Submitted Manuscript version 6
28 Nov 2022 Reviewed Reviewer Report
3 Jan 2023 Author responded Author comments - Hongbin Gu
Resubmission - Version 7
3 Jan 2023 Submitted Manuscript version 7
17 Jan 2023 Reviewed Reviewer Report
14 Feb 2023 Reviewed Reviewer Report
24 Feb 2023 Author responded Author comments - Hongbin Gu
Resubmission - Version 8
24 Feb 2023 Submitted Manuscript version 8
29 Mar 2023 Author responded Author comments - Hongbin Gu
Resubmission - Version 9
29 Mar 2023 Submitted Manuscript version 9
Publishing
4 Apr 2023 Editorially accepted
19 Apr 2023 Article published 10.1186/s12871-023-02077-1

You can find further information about peer review here.

Back to article page